| 纯度 | > 90 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | CD59 |
| Uniprot No | P13987 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 26-102aa |
| 氨基酸序列 | MASMTGGQQMGRGHHHHHHGNLYFQGGEFALVQCYNCPNPTADCKTAVNC SSDFDACLITKAGLQVYNKCWKFEHCNFNDVTTRLRENELTYYCCKKDLC NFNEQLEN |
| 预测分子量 | 12 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CD59重组蛋白的3篇代表性文献及其摘要概括：
---
1. **文献名称**：*"Structure of Human CD59 in Complex with a Complement C5b-8 Complex"*
**作者**：Hinchliffe, S.J., et al.
**摘要**：该研究解析了人源CD59蛋白与补体C5b-8复合物结合的晶体结构，揭示了CD59通过特异性结合补体成分C8α链抑制膜攻击复合物(MAC)形成的分子机制，为设计基于CD59的重组蛋白疗法提供了结构基础。
---
2. **文献名称**：*"Recombinant Soluble CD59 Protein Protects Neurons from Synaptic Damage in Experimental Autoimmune Encephalomyelitis"*
**作者**：Okamoto, N., et al.
**摘要**：通过在大肠杆菌中表达重组可溶性CD59蛋白，研究发现其在实验性自身免疫性脑脊髓炎(EAE)模型中能够有效抑制补体介导的突触损伤，表明重组CD59在神经炎症性疾病治疗中的潜在应用价值。
---
3. **文献名称**：*"Functional Characterization of Recombinant CD59 in Xenotransplantation Models"*
**作者**：Fiane, A.E., et al.
**摘要**：利用哺乳动物细胞表达系统制备重组CD59蛋白，并在异种移植模型中验证其抑制补体激活的能力，证明其可显著延缓移植物排斥反应，提示其在器官移植免疫调控中的临床应用前景。
---
**备注**：上述文献均为示例，实际引用时建议通过PubMed或专业数据库(如ScienceDirect)核对具体信息。如需近期研究，可关注2020年后关于CD59重组蛋白在肿瘤免疫或罕见病治疗中的新进展。
CD59. also known as MAC-inhibitory protein or protectin, is a glycosylphosphatidylinositol (GPI)-anchored membrane protein that plays a critical role in regulating the complement system, an essential component of innate immunity. It functions by binding to complement proteins C8 and C9 during the assembly of the membrane attack complex (MAC), thereby preventing pore formation on host cell membranes and protecting them from unintended complement-mediated lysis. This self-defense mechanism is vital for maintaining cellular integrity, particularly in tissues exposed to complement activation.
The recombinant CD59 protein is produced using genetic engineering techniques, where the CD59 gene is cloned into expression systems such as mammalian cells, bacteria, or yeast. Recombinant expression allows large-scale production of soluble or membrane-bound CD59 variants, often modified to enhance stability or functionality. Unlike native CD59. recombinant forms may lack GPI anchors but can retain complement-inhibitory activity depending on the expression system and purification methods. Researchers frequently employ these proteins to study complement regulation mechanisms, screen for therapeutic agents, or engineer cell-based therapies.
Clinically, CD59 dysfunction or deficiency is linked to diseases like paroxysmal nocturnal hemoglobinuria (PNH) and age-related macular degeneration. Recombinant CD59 has therapeutic potential in treating complement-mediated disorders, either as a standalone drug or in combination with existing therapies like anti-C5 antibodies. Additionally, it serves as a tool in cancer research, where altered CD59 expression may influence tumor immune evasion. Despite challenges in maintaining structural fidelity during production, advances in protein engineering continue to expand its biomedical applications.
×
